Translational Dermatology Unit
The Translational Dermatology Unit has established successful 'bench to bedside' capability which puts it in prime position to target the huge unmet medical need associated with skin diseases.
©
Image by freepik
context
The Translational Dermatology Unit forms part of the MRC Translational Immune Discovery Unit at the MRC Weatherall Institute of Molecular Medicine within the Radcliffe Department of Medicine.
We have built extensive capabilities in driving discovery and therapeutics for inflammatory skin diseases, which carry an enormous burden on patients and their families worldwide. Through longstanding Medical Research Council and Wellcome Trust funding, we have created a state-of-the-art suite of technologies which have successfully driven fundamental scientific advances and identified novel therapeutic targets.
Successfully implemented technologies include extensive single cell approaches such as multiple spatial transcriptomics and imaging platforms. Many of these have progressed towards patient benefit through commercialisation of technologies and assets in licensing, advisory roles and spin-outs.
This activity is complemented by an existing strong clinical infrastructure including research nurses, committed and experienced dermatology consultants, junior medical staff and administrative support, with over 60,000 patient attendances a year.
ambition
Our aim now is to build on these strong foundations to increase our scope, scale, reach and impact in order to unlock the potential to drive discovery and therapeutic benefit for patients.
Specifically, we want to grow increased experimental medicine activity with expanded clinical trial capability underpinned by accredited sample handling and bespoke state-of-the-art analytical and discovery capability.
Our research
Our aim is to understand, at the molecular and cellular level, the role of human cutaneous immune responses in mechanisms of disease, treatment and vaccination